Boehringer advances hep C contender into pivotal trial

Boehringer Ingelheim has begun enrolling patients in a pivotal late-stage hepatitis C study. The therapy combines faldaprevir (BI 201335), a protease inhibitor administered once daily, and BI 207127, a non-nucleoside polymerase inhibitor taken twice daily, plus ribavirin. BI's hep C program represents a new Phase III contender in the race to develop the world's first interferon-free treatment, a field now dominated by Gilead ($GILD) and AbbVie ($ABBV). "Our investigational interferon-free regimen has shown particular promise in treating patients with HCV genotype-1b so we have decided to enroll these patients in our Phase 3 trial program. Our goal is for an interferon-free future and ensuring patients are treated with the most effective treatment for them individually," said Peter Piliero, M.D., vice president, clinical development and medical affairs. Release

 

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.